Did Guardian Pharmacy beat or miss consensus estimates last quarter?

What does Guardian Pharmacy do and what are its main business segments?

What were the key takeaways from Guardian Pharmacy’s earnings call?

What is the market's earnings forecast for Guardian Pharmacy next quarter?

What is the revenue and EPS growth rate for Guardian Pharmacy year over year?

What is Guardian Pharmacy's gross profit margin?

What factors drove the changes in Guardian Pharmacy's revenue and profit?

What were the key takeaways from Guardian Pharmacy's earnings call?

- **Record 2025 Performance**: 13% organic revenue growth, 27% EBITDA expansion to $115 million, and 7.9% margin. Vaccines drove $56M resident savings and 120K scripts.
- **2026 Outlook**: EBITDA guidance raised to $120-$124M, reflecting 8.6% margin target. IRA mitigation strategies in place, with $65M 2027 branded drug headwind.
- **Operational Excellence**: 21.5% gross margin in Q4, 60% cash conversion rate, and 90 basis point margin drag from greenfield investments.
- **Strategic Growth**: Active M&A pipeline, 4Q acquisitions onboarding national accounts faster, and 90%+ generic script mix driving margin balance.

**【CEO Summary Section】**
- **2025 Full Year Performance**: Organic revenue growth of 13%, driven by new resident additions, script growth, and higher acuity. Adjusted EBITDA grew 27% to $115 million, with margins expanding 50 basis points to 7.9%. Acquisitions contributed to reported revenue growth of 18%.
- **Operational Highlights**: 100,000 clinical interventions, $56 million in resident cost savings, and 120,000 vaccines administered. Investments in data analytics and customer service (e.g., GuardianHub) enhanced operational efficiency.
- **2026 Outlook**: Adjusted EBITDA guidance raised to $120-$124 million, reflecting low double-digit growth. Revenue forecast maintained at $1.4-$1.42 billion, accounting for IRA pricing impacts. Focus on offsetting IRA-related headwinds and leveraging demographic tailwinds.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Revenue of $397.6 million (17% YoY growth), gross profit of $85.5 million (27% YoY), and adjusted EBITDA of $39.5 million (53% YoY). Gross margin expanded to 21.5% due to vaccine profitability improvements, greenfield contributions, and plan optimization.
- **Balance Sheet Strength**: Cash balance increased to $66 million, supporting 4 acquisitions and greenfield investments. Cash conversion rate of 60% enabled capital deployment while maintaining financial flexibility.
- **2026 Guidance**: Effective tax rate expected at 26%. Stock-based compensation expense to step up to $3 million quarterly. Long-term focus on managing branded drug negotiations under IRA (e.g., $65 million 2027 headwind).

**【Q&A Key Highlights】**
- **Vaccine Profitability**: Q4 vaccine margins expanded due to better purchasing and reimbursement. This trend is durable, contributing to 2026 margin expansion.
- **IRA Mitigation**: Company expects to offset IRA-related EBITDA impact in 2026. Monitoring operational adjustments to minimize disruption.
- **M&A Pipeline**: Robust pipeline with focus on like-minded operators in key markets. Pacific Northwest acquisitions achieved faster synergies, reducing margin drag by 90 basis points.
- **Labor Efficiency**: Scale-driven labor leverage and operational improvements (e.g., Medicare Part D mix) support margin expansion.


Guardian Pharmacy Services, Inc.(GRDN)-20260312-2025 Q4 Earnings call transcript

- **Top-Line Momentum**: 20% revenue growth and 19% EBITDA expansion highlight execution strength despite policy headwinds.
- **Margin Resilience**: 7.2% EBITDA margin maintained through disciplined integration of 11 new pharmacies in 24 months.
- **Strategic Flexibility**: S-3 filing and lockup provide capital market flexibility, while Pacific Northwest expansion positions for long-term growth.
- **Operational Excellence**: 60%+ cash conversion and 16% EBITDA growth underscore financial discipline and scalability.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached $377 million, up 20% YoY, driven by 13% resident count growth to 203,766 and strong vaccine program performance.
- **EBITDA Expansion**: Adjusted EBITDA rose 19% to $27.3 million, despite 10 basis points margin dilution from recent acquisitions and greenfield pharmacies.
- **Policy Navigation**: Management emphasized proactive engagement with payers to mitigate Inflation Reduction Act headwinds, while maintaining flat 2026 revenue guidance.
- **Strategic Priorities**: Focus on organic growth (new ALF partnerships, greenfield expansion), disciplined M&A (Pacific Northwest acquisitions), and operational efficiency through technology and procurement.

**【CFO Financial Commentary】**
- **Financial Flexibility**: Filed S-3 shelf registration for up to 6 million shares, with 93% of pre-IPO shares locked up until June 2026.
- **Guidance Update**: Raised 2025 revenue to $1.43-$1.45 billion (prev. $1.39-$1.41B) and EBITDA to $104-$106 million (prev. $100-$102M), reflecting 16% YoY EBITDA growth.
- **Margin Management**: 7.2% adjusted EBITDA margin (flat QoQ), with 4-5-year pharmacies performing at or above consolidated margins.
- **Cash Flow Strength**: $36 million cash on hand, up $18 million QoQ, with 60%+ cash conversion ratio.

**【Q&A Highlights】**
- **Vaccine Program**: Q3 vaccine revenue was stronger than prior years, with September clinics outperforming expectations. Q4 impact expected to be steady despite broader market vaccine hesitancy.
- **Acquisition Integration**: 2-3-year-old acquisitions tracking toward consolidated margins, with 4+ year pharmacies exceeding company average.
- **Part D Dynamics**: Resident acuity trends driving higher brand utilization, though no significant shift in plan mix (MA-PD vs. stand-alone) observed yet.
- **Policy Outlook**: Ongoing PBM negotiations expected to offset EBITDA headwinds, with focus on value-based care models.

Guardian Pharmacy Services, Inc. (GRDN) Q3 2025 Earnings Call Transcript

- **Revenue & Profit Growth**: Q2 revenue up 15% to $344.3M, EBITDA $25M (+15% YoY), with 7.2% margins maintained amid 3 new acquisitions.
- **Expansion Momentum**: Added 3 pharmacies (Wichita, Seattle, Naples) and Oregon acquisition; 11 early-stage pharmacies to drive 2025 growth.
- **Clinical Impact**: 50,000+ interventions YTD, $24M savings via insurance optimization, and expanding falls management program.
- **Policy Resilience**: Proactive PBM negotiations and advocacy efforts to mitigate IRA drug pricing impacts; 2026 branded drug revenue at risk but confident in resolution.
- **Financial Strength**: $18.8M cash, no debt, and updated guidance raising revenue to $1.41B and EBITDA to $102M.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue reached $344.3 million, up 15% YoY, driven by 12% resident count growth to 195,000 and double-digit organic growth. Adjusted EBITDA was $25 million (+15% YoY), maintaining 7.2% margins despite integrating 3 acquisitions and 1 greenfield.
- **Acquisition Activity**: Added 3 pharmacies (2 via acquisition in Wichita, KS and Seattle, WA; 1 greenfield in Naples, FL), with Oregon acquisition contributing post-quarter. Total 2025 pipeline includes 11 early-stage pharmacies (high single-digit revenue impact, no EBITDA contribution).
- **Clinical Innovation**: Expanded falls management program to Florida, achieving 50,000+ clinical interventions YTD and $24M in insurance savings. Antibiotic stewardship and psychotropic monitoring programs also delivered cost reductions.
- **Public Company Transition**: Completed secondary offering, doubling public float to 17.8M shares, enhancing liquidity and employee alignment (30% ownership retained). Vaccine program seasonal impact expected to repeat Q4 profitability.
- **Policy Challenges**: IRA drug pricing changes may reduce 2026 branded drug revenue by 50%, but progress made in PBM negotiations. Advocacy efforts continue for long-term care pharmacy policy support.

**【CFO Financial Commentary】**
- **Balance Sheet Strength**: Cash increased $4.8M to $18.8M, supporting 2 Q2 acquisitions and greenfield launch. No debt under credit facility; revolver provides growth flexibility.
- **Updated Guidance**: Full-year revenue raised to $1.39B-$1.41B (+$60M YoY), EBITDA to $100M-$102M (+$10M YoY). Q4 seasonal vaccine activity expected to mirror 2024 profitability. EBITDA margins ~7.2% for remainder of year, with 8%+ from mature pharmacies.
- **Cost Management**: $1.1M public company costs offset by strong operating discipline. Stock-based compensation to decline $1M in Q4 as pre-IPO equity program sunsets.

**【Q&A Highlights】**
- **Vaccine Program**: Steady-state growth with no incremental Q4 inflection; 2024 profitability repeat expected.
- **PBM Negotiations**: Progress made with payers; resolution timing TBD but expected before Q4 guidance update.
- **Organic Growth Drivers**: Patient acuity (complex prescriptions), brand inflation, and Part D plan optimization driving high-single-digit organic growth.
- **Acquisition Pipeline**: Strongest in 5 years, limited by human capital capacity. Oregon and Washington acquisitions target 25% market share in key regions.
- **Public Company Benefits**: Increased visibility and talent attraction, with no material impact on acquisition pipeline or strategy.

Guardian Pharmacy Services (GRDN)-11 Aug 25-2025 Q2 Earnings call transcript

- **Strong Q1 Growth**: 20% revenue rise, 16% EBITDA expansion, and 15% resident count growth highlight strong execution.
- **Acquisition Strategy**: 52 pharmacies now, with 10 new sites (<2 years old) on track for 3-4-year margin integration.
- **Risk Management**: Tariff-proof Part D model and cautious IRA negotiation stance mitigate risks.
- **Cost Visibility**: $4M annual integration costs vs. $1M in 2024, with $500K Q1 acceleration.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue reached $329 million, up 20% YoY, driven by organic growth and acquisitions (Heartland and Freedom pharmacies). Resident Count rose 15% to 189,000, and adjusted EBITDA increased 16% to $23.4 million.
- **Acquisition and Expansion**: Acquired a Wichita, KS pharmacy (total 52 locations) and launched greenfield pharmacies in Columbus, OKC, Omaha, and Naples. Integration playbook targets 3-4 years to achieve margin parity.
- **Tariff and IRA Impact**: 70% of revenue from Part D protects against branded drug tariffs. Generic drugs face limited price hikes due to competition. IRA negotiations remain ongoing, with potential 2026 impact.

**【CFO Financial Commentary】**
- **Q1 Financials**: GAAP revenue $329.3M (+20%), gross profit $64.4M (+17%), adjusted EBITDA $23.4M (+16%). Cash balance $14M, no debt.
- **Integration Costs**: Accelerated Heartland IT conversion added $500K in Q1 costs, delaying profitability. 10 of 52 pharmacies (<2 years old) are dilutive but expected to ramp up margins.
- **Guidance**: Full-year revenue ($1.33B-$1.35B) and EBITDA ($97M-$101M) targets remain. Q2 similar to Q1, with potential flattish EBITDA due to integration expenses.

**【Q&A Key Highlights】**
- **Heartland Integration**: $500K of Q1 costs were pulled forward from Q2/Q3. Full-year impact ~$4M, up from $1M in 2024.
- **Policy Uncertainty**: Trump's executive order on PBMs may complicate IRA negotiations. Management expects resolution via judiciary or Congress.
- **Acquisition Pipeline**: Robust pipeline with several near-term opportunities, driven by industry stress from tariffs and IRA.

Actual	0.275	0.19	0.15	0.23	0.25	0.37
Forecast	0.1921	0.22	0.22	0.1933	0.235	0.2675
Surprise	+43.15%	-13.64%	-31.82%	+18.99%	+6.38%	+38.32%

Actual	314.39M	338.57M	329.31M	344.33M	377.43M	397.62M
Forecast	303.13M	332.77M	321.21M	331.33M	354.15M	390.04M
Surprise	+3.72%	+1.74%	+2.52%	+3.92%	+6.57%	+1.94%

GRDN

GRDN fundamentals

GRDN Q4 2025 Earnings

Earnings Call

You can ask Aime

GRDN

GRDN fundamentals

GRDN Q4 2025 Earnings

Earnings Call

GRDN Earnings Call Summary for Q4/20254:30 PM on Mar 11, 2026

GRDN Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

GRDN Earnings Call Summary for Q2/20254:30 PM on Aug 11, 2025

GRDN Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

GRDN Earnings Call Summary for Q4/20244:30 PM on Mar 26, 2025

You can ask Aime